StoneChecker gets CE Mark for its kidney stone analysis software

Imaging software developer StoneChecker gets CE Mark for its kidney stone analysis product.

StoneChecker, a U.K.-based medical software developer that is part of Flying Brands, said it has received a CE Mark for its software that analyzes kidney stones.

The medical imaging software provides a detailed analysis of kidney stones that gives physicians and clinicians critical information to formulate the most effective treatment for each patient, StockMarketWire reported.

The product uses a TexRAD developed algorithm to examine kidney stone heterogeneity and "texture" not visible to the naked eye, according to the company’s website.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The approval opens the door for StoneChecker to begin marketing the software across Europe. 

"Obtaining a CE mark for StoneChecker Software's first product comfortably before the end of the year target has been a significant accomplishment for the agile multidisciplinary Stone Checker team,” Trevor Brown, the CEO of Flying Brands, said in a statement. “I share the team's excitement as we prepare to approach the markets now available to us.”


Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Exact Sciences received an FDA breakthrough designation for its liver cancer blood test as it finalized its $2.8 billion merger with Genomic Health.